Clinical trials: Neuroepithelial Tumor
Retinoblastoma
A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma
Over the past 15 years, intravenous chemotherapy has become the most popular conservative (eye-saving) method for retinoblastoma treatment because it is often effective and usually safe.
- Trial name
- IAC-RB (NCT00857519)
- Testing
- Melphalan, Carboplatin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wills Eye
Metastatic Colorectal Cancer, Glioblastoma
Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma
The treatment of the most common cancers (colon, breast, lung, liver and kidney) has recently added a new therapeutic class known as the "anti-angiogenic".
- Conditions
- Metastatic Colorectal Cancer, Glioblastoma, Bevacizumab, Capillaroscopy
- Trial name
- BEVACAPI (NCT01810744)
- Testing
- capillaroscopy, blood pressure measurement
- Where
- France
- Volunteers
- 47 people
- Sponsor
- Centre Georges Francois Leclerc
Glioblastoma, Malignant Glioma
Treatment Response and Prognosis in Glioma Patients: Q Cell and Its Biological Characteristics
The purpose of this study is to determine whether Q cells separated from the glioma sample are determinants in treatment response and prognosis of glioma patients
- Trial name
- NCT02047058
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Glioma, Glioblastoma
Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma
This phase II trial studies the side effects of solriamfetol in improving sleep in patients with grade II-IV glioma. Solriamfetol is a wakefulness-promoting drug.
- Trial name
- JAZZ (NCT03868943)
- Testing
- Soliramfetol
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences
Medulloblastoma
CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation
The study is being done to learn more about the long-term health and well-being of participants treated for medulloblastoma. The study is to decide which evaluations focusing on therapy-related lasting effects (or toxicities)…
- Trial name
- NCT07085325
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- St. Jude Children's Research Hospital
Glioblastoma
A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
The purpose of this study is to assess progression-free survival (PFS) and overall survival (OS) in newly diagnosed Glioblastoma (GBM) participants treated with IGV-001 as compared with placebo.
- Trial name
- NCT04485949
- Testing
- IGV-001 Cell Immunotherapy, Standard of Care (SOC): Radiation Therapy, SOC: Temozolomide
- Where
- 23 sites in United States
- Volunteers
- 99 people
- Sponsor
- Imvax
Glioma, IDH Mutation
Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma
This study aims to look at how BAY 2402234 responds in body in patients with recurrent glioma.
- Trial name
- NCT05061251
- Testing
- BAY 2402234
- Sponsor
- University of Texas Southwestern Medical Center
Recurrent Glioblastoma, Recurrent Malignant Glioma
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
This phase I trial studies the side effects and best dose of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain in treating patients with MPP2+ glioblastoma that has come back (recurrent) or that is…
- Conditions
- Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma
- Trial name
- NCT04214392
- Testing
- Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery), Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- City of Hope Medical Center
Neuroblastoma, Relapsed Neuroblastoma
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma
The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.
- Conditions
- Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma
- Trial name
- NCT04023331
- Testing
- 67Cu-SARTATE, 64Cu-SARTATE
- Where
- 8 sites in United States
- Volunteers
- 21 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Astrocytoma, Glioma
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
Background: Glioblastoma (GBM) is a cancer of the brain. Current survival rates for people with GBM are poor; survival ranges from 5.2 months to 39 months.
- Conditions
- Astrocytoma, Glioma, Recurrent Glioblastoma
- Trial name
- NCT06344130
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: NBI-3001 may be able to locate cancer cells and stop them from growing. This may be an effective treatment for glioblastoma multiforme.
- Trial name
- NCT00014677
- Testing
- interleukin-4 PE38KDEL cytotoxin, conventional surgery
- Where
- 4 sites in United States
- Sponsor
- Neurocrine Biosciences
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma
Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma
This research trial is studying how Ch14.18 acts in the body of younger patients with high-risk neuroblastoma. Studying samples of blood from patients with cancer receiving Ch14.18 may help doctors learn more about how this drug…
- Conditions
- Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neurotoxicity Syndrome, Pain
- Trial name
- NCT01418495
- Testing
- Cytology Specimen Collection Procedure, Pharmacological Study
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Glioma
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
This is an open-label, multicenter, Phase 1 study to establish the safety and efficacy/tolerability of a single dose of 186RNL by the intraventricular route (via intraventricular catheter) for recurrence glioma in patients who…
- Trial name
- NCT05460507
- Testing
- Retreatment Rhenium Liposome
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cerenome
Burkitt Lymphoma, Retinoblastoma
Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment
Digital case management systems have the potential to increase compliance with protocol-driven treatment, reduce treatment abandonment and ultimately help to close the discrepancy in pediatric cancer outcomes between Low and…
- Conditions
- Burkitt Lymphoma, Retinoblastoma, Diffuse Large B-cell Lymphoma
- Trial name
- NCT03677128
- Testing
- mNavigator
- Where
- Tanzania
- Volunteers
- 75 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors, Kidney Cancer
Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors
RATIONALE: Tubefeeding may help maintain good nutrition and lessen weight loss in younger patients receiving chemotherapy for cancer.
- Conditions
- Brain and Central Nervous System Tumors, Kidney Cancer, Leukemia, Liver Cancer
- Trial name
- NCT00624962
- Testing
- nutritional intervention, therapeutic nutritional supplementation
- Sponsor
- Vanderbilt University
Glioblastoma Multiforme
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
The purpose of this study is to evaluate the objective response rate and 6-month progression-free survival rate of XL184 in subjects with recurrent or progressive glioblastoma multiforme.
- Trial name
- NCT00704288
- Testing
- XL184
- Where
- 8 sites in United States
- Volunteers
- 222 people
- Sponsor
- Exelixis
EphA2 Positive Malignant Glioma, CAR-T Cell Immunotherapy
CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with EphA2 positive malignant glioma patients.
- Trial name
- NCT02575261
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Brain and Central Nervous System Tumors, Metastatic Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. This may be effective treatment for primary or metastatic brain tumors.
- Conditions
- Brain and Central Nervous System Tumors, Metastatic Cancer, Neuroblastoma
- Trial name
- NCT00003461
- Testing
- surgical procedure, astatine At 211 monoclonal antibody 81C6
- Where
- United States
- Sponsor
- Duke University
Neuroblastoma, Pheochromocytoma
Expanded Access Protocol Using 131I-MIBG
Protocol JDI2007-01 is an Expanded Access Protocol with therapeutic 131I-MIBG for patients with neuroblastoma or pheochromocytoma / paraganglioma, who otherwise do not qualify for available treatments, or where approved treatment…
- Conditions
- Neuroblastoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT01590680
- Testing
- I-131 MIBG
- Where
- 19 sites in United States
- Sponsor
- Jubilant DraxImage Inc.
Glioblastoma
Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma
The purpose of this study is to determine whether bevacizumab and nimustine are effective in the treatment of recurrent high grade glioma and to explore whether there is any subgroup being sensitive to this therapeutic protocol.
- Trial name
- NCT02698280
- Testing
- Bevacizumab, Nimustine
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Huashan Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.